As per a recent information published on 25/05/2020, the trade name of a medicinal product Allopurinol has been changed to a new name to accentuate the brand’s identity and make it more noticeable in the allopurinol market, announced a renowned Russian pharmaceutical organization recently. This drug is used for the treatment and prevention of diseases due to hyperuricemia, elevated levels of uric acid in the blood. 

What makes the new drug stand out is its exclusive indication- all types of hyperuricemia that cannot be management by the dietary changes, like secondary hyperuricemia, a clinical complication of hyperuricemia, especially acue gout, urate nephropathy, along with dissolution and prevention of the development of uric acid crystals. A clear distinction of this drug, will enable the physicians and pharmacists to pick a drug with significant features for the patient in a specified pharmaco therapeutic group.

This drug allopurinol drug has been bestowed the Russian Pharma Awards 2016 nominated as “The most recommended drug with an escalated level of uric acid”. This became an acknowledged leader in its category with a market share of almost 80%.